Becton, Dickinson and Company

Becton, Dickinson and Company

BDXยทNYSE

$145.61

+0.19%
HealthcareMedical - Instruments & Supplies

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

At a Glance

Live Snapshot
Market Cap$52.75B
EPS5.8400
P/E Ratio24.93
Earnings Date08/06/2026
4.73%
Return on Invested Capital
18%
3Y+7.0%
5Y+198.0%
10Y-19.0%
6.61%
Return on Equity
3Y-6.0%
5Y+80.0%
10Y-48.0%
3.03%
Return on Assets
2%
3Y-10.0%
5Y+87.0%
10Y-20.0%
Becton, Dickinson and Company

Becton, Dickinson and Company Management Team

BDX ยท NYSE
MC

Mr. Christopher J. DelOrefice CPA

Executive Vice President & Chief Financial Officer

Compensation

$1,777,376

Born 1971(Age 55)
male
MS

Ms. Shana Carol Neal

Executive Vice President & Chief People Officer

Compensation

$1,387,319

Born 1966(Age 60)
female
ME

Ms. Elizabeth McCombs

Executive Vice President & Chief Technology Officer

Born 1977(Age 49)
female
MR

Mr. Richard Byrd

Executive Vice President & President of Interventional Segment

Compensation

$1,374,985

Born 1968(Age 58)
male
MM

Mr. Michael Garrison

Executive Vice President & President of Medical segment

Compensation

$1,332,675

Born 1970(Age 56)
male
MD

Ms. Denise Russell Fleming

Executive Vice President of Technology & Global Services and Chief Information Officer

Born 1970(Age 56)
female
MT

Mr. Thomas E. Polen Jr.

President, Chief Executive Officer & Chairman

Compensation

$3,733,112

Born 1973(Age 53)
male
DJ

Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D.

Senior Vice President & Chief Scientific Officer

MP

Ms. Pamela L. Spikner

Senior Vice President, Chief Accounting Officer & Controller

Born 1978(Age 48)
female
MG

Mr. Greg Rodetis

Senior Vice President, Treasurer & Head of Investor Relations

male
bdx

Becton, Dickinson and Company Insider Positioning

BDX ยท NYSE

During the last 12 months, insiders have purchased $1.01M and sold $923K worth of BDX shares, resulting in $82K of net buying activity.

3 Months

Bought

0

0.00

Sold

224

34.06K

Net Activity

-34K

-$34K

3-6 Months

Bought

0

0.00

Sold

2.4K

466.08K

Net Activity

-466K

-$466K

6-9 Months

Bought

0

0.00

Sold

1.3K

245.86K

Net Activity

-246K

-$246K

9-12 Months

Bought

5.3K

1.01M

Sold

921

177.42K

Net Activity

+828K

+$828K

Top Buyers

1
HG

Hayes Gregory

Director

5.3K sharesโ€ข1 transactions

$1.01M

Top Sellers

1
FC

Fraser Claire

Director

1.8K sharesโ€ข2 transactions

$338K

2
GMD

Garrison Michael David

Officer: Evp & Pres Med.Essntl&Biopharm

1.2K sharesโ€ข3 transactions

$249K

3
SBL

Scott Bertram L

Director

1.2K sharesโ€ข2 transactions

$212K

4
FM

Feld Michael

Officer: Evp, Chief Revenue Officer

695 sharesโ€ข10 transactions

$124K

Insider Activity Analysis

Net Insider Sentiment

Bullish

Moderately bullish with $82K net buying. Insiders show cautious optimism through measured share purchases.

Buy/Sell Ratio

1.09:1

Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.

Recent Trend (3 Months)

$34K

Heavy recent selling activity. Recent insider sales notably exceed purchasesโ€”may warrant investigation into company developments.

Insider Participation

High Selling

4 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.

Insider Activity Insight

Balanced insider activity: Roughly equal buying and selling suggests normal portfolio management rather than strong directional signals. Look to other metrics for clearer investment insights.

SEC Filings

BDX - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
DEF 14A

DEF 14A 2025

N/A

December 18, 2025
December 12, 2025
2025
DEF 14A

DEF 14A 2024

N/A

December 19, 2024
December 16, 2024
2024
DEF 14A

DEF 14A 2023

N/A

December 14, 2023
December 14, 2023
2023
DEF 14A

DEF 14A 2022

N/A

December 15, 2022
December 12, 2022
2022
DEF 14A

DEF 14A 2021

N/A

December 16, 2021
December 16, 2021
2021
DEF 14A

DEF 14A 2020

N/A

December 17, 2020
December 17, 2020
2020
DEF 14A

DEF 14A 2019

N/A

December 03, 2018
January 22, 2019
2019
DEF 14A

DEF 14A 2018

N/A

December 14, 2017
January 23, 2018
2018
DEF 14A

DEF 14A 2017

N/A

December 15, 2016
January 24, 2017
2017
DEF 14A

DEF 14A 2016

N/A

December 17, 2015
January 26, 2016
2016
Showing 1 to 10 of 32 filings